A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Completed

Phase 1 Results N/A

Summary of Purpose

The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke. The study is not designed to establish efficacy, although preliminary explorations will be conducted.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 16 March 2014.

1 Dec 2010 7 Jan 2011 Unavailable 1 Jul 2013 1 Mar 2014 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Single Group Assignment

Contacts

  • Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:

    JNJ.CT@sylogent.com